<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2709211085
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Omnicef 250mg/5ml Suspension
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFDINIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        101.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Omnicef 250 mg/5 ml Powder for Oral Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml contains 250 mg cefdinir.

Excipients with known effect: Sodium benzoate and sugar.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off-white powder with a characteristic strawberry smell. 

After reconstitution, it is a white to off-white suspension with strawberry flavor.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Omnicef and other&nbsp;antibacterial&nbsp;drugs, Omnicef should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><p>Omnicef is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.</p><p><u>Pediatric patients</u></p><p><strong>Acute bacterial otitis media&nbsp;</strong></p><p>Caused by&nbsp;<em>Haemophilus influenzae</em>&nbsp;(including &beta;-lactamase producing strains),&nbsp;<em>Streptococcus pneumoniae</em>&nbsp;(penicillin-susceptible strains only), and&nbsp;<em>Moraxella catarrhalis</em>&nbsp;(including &beta;-lactamase producing strains).</p><p>Acute maxillary sinusitis</p><p>Caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;lactamase producing strains).</p><p>Pharyngitis/tonsillitis</p><p>Caused by&nbsp;<em>Streptococcus pyogenes</em>&nbsp;</p><p>Note:&nbsp;Cefdinir is effective in the eradication of&nbsp;<em>S. pyogenes </em>from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following&nbsp;<em>S. pyogenes </em>pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.</p><p>Uncomplicated skin and skin structure infections</p><p>Caused by&nbsp;<em>Staphylococcus aureus</em>&nbsp;(including &beta;-lactamase producing strains) and&nbsp;<em>Streptococcus pyogenes</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Powder for oral suspension</strong></p><p>The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in skin infections; therefore, Omnicef Powder for Oral Suspension should be administered twice daily in this infection. Omnicef Powder for Oral Suspension may be administered without regard to meals.</p><p><em>Pediatric patients (age 6 months through 12 years)</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Type of Infection</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute Bacterial Otitis Media</p></td><td style="vertical-align:top"><p>7 mg/kg q12h or 14 mg/kg q24h</p></td><td style="vertical-align:top"><p>5 to 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute Maxillary Sinusitis</p></td><td style="vertical-align:top"><p>7 mg/kg q12h or&nbsp;14 mg/kg q24h</p></td><td style="vertical-align:top"><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis/Tonsillitis</p></td><td style="vertical-align:top"><p>7 mg/kg q12h or 14 mg/kg q24h</p></td><td style="vertical-align:top"><p>5 to 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated Skin and Skin Structure Infections</p></td><td style="vertical-align:top"><p>7 mg/kg q12h</p></td><td style="vertical-align:top"><p>10 days</p></td></tr></tbody></table><p><em>Omnicef Powder for Oral Suspension pediatric dosage chart</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Weight</strong></p></td><td style="vertical-align:top"><p><strong>125 mg/5 ml</strong></p></td><td style="vertical-align:top"><p><strong>250 mg/5 ml</strong></p></td></tr><tr><td style="vertical-align:top"><p>9 kg/20 lbs</p></td><td style="vertical-align:top"><p>2.5 ml q12h or 5 ml q24h</p></td><td style="vertical-align:top"><p>Use 125 mg/5 ml product</p></td></tr><tr><td style="vertical-align:top"><p>18 kg/40 lbs</p></td><td style="vertical-align:top"><p>5 ml q12h or 10 ml q24h</p></td><td style="vertical-align:top"><p>2.5 ml q12h or 5 ml q24h</p></td></tr><tr><td style="vertical-align:top"><p>27 kg/60 lbs</p></td><td style="vertical-align:top"><p>7.5 ml q12h or 15 ml q24h</p></td><td style="vertical-align:top"><p>3.75 ml q12h or 7.5 ml q24h</p></td></tr><tr><td style="vertical-align:top"><p>36 kg/80 lbs</p></td><td style="vertical-align:top"><p>10 ml q12h or 20 ml q24h</p></td><td style="vertical-align:top"><p>5 ml q12h or 10 ml q24h</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 43 kg<sup>a</sup>/95 lbs</p></td><td style="vertical-align:top"><p>12 ml q12h or 24 ml q24h</p></td><td style="vertical-align:top"><p>6 ml q12h or 12 ml q24h</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>Pediatric patients who weigh &gt; 43 kg should receive the maximum daily dose of 600 mg.</p></td></tr></tbody></table><p><em>Patients with renal insufficiency</em></p><p>For adult patients with creatinine clearance &lt; 30 ml/min, the dose of cefdinir should be 300 mg given once daily.</p><p>Creatinine clearance is difficult to measure in outpatients. However, the following formula may be used to estimate creatinine clearance (CLcr) in adult patients. For estimates to be valid, serum creatinine levels should reflect steady-state levels of renal function.</p><table border="0" cellspacing="0" cellpadding="0" style="width:450px"><tbody><tr><td rowspan="2"><p>Males:</p></td><td><p><u>(weight in kg) x (140 &ndash; age)</u></p></td></tr><tr><td><p>(72) x serum creatinine</p></td></tr><tr><td><p>Females:</p></td><td><p>CLcr =0.85 &times; above value</p></td></tr></tbody></table><p>where creatinine clearance is in ml/min, age is in years, weight is in kilograms, and serum creatinine is in mg/dl.</p><p>The following formula may be used to estimate creatinine clearance in pediatric patients:</p><p>CLcr =&nbsp;K &times; body length or height/serum creatinine</p><p>Where K = 0.55 for pediatric patients older than 1 year<sup> </sup>and 0.45 for infants (up to 1 year).</p><p>In the above equation, creatinine clearance is in ml/min/1.73 m&sup2;, body length or height is in centimeters, and serum creatinine is in mg/dl.</p><p>For pediatric patients with a creatinine clearance of &lt; 30 ml/min/1.73 m&sup2;, the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily.</p><p><em>Patients on hemodialysis</em></p><p>Hemodialysis&nbsp;removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300-mg or 7-mg/kg dose every other day.</p><p>At the conclusion of each hemodialysis session, 300 mg (or 7 mg/kg) should be given. Subsequent doses (300 mg or 7 mg/kg) are then administered every other day.</p><p><em>Pediatric use</em></p><p>Safety and efficacy in neonates and infants less than 6 months of age have not been established. Use of cefdinir for the treatment of acute maxillary&nbsp;sinusitis&nbsp;in pediatric patients (age 6 months through 12 years) is supported by evidence from adequate and well-controlled studies in adults and adolescents, the similar&nbsp;pathophysiology&nbsp;of acute sinusitis in adult and pediatric patients, and comparative pharmacokinetic data in the pediatric population.</p><p><em>Geriatric use</em></p><p>Efficacy is comparable in geriatric patients and younger adults. While cefdinir has been well-tolerated in all age groups, in clinical trials geriatric patients experienced a lower rate of adverse events, including diarrhea, than younger adults. Dose adjustment in elderly patients is not necessary unless renal function is markedly compromised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Omnicef (cefdinir) is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Warnings</u></p><p>Before therapy with Omnicef (cefdinir) is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefdinir, other cephalosporins, penicillins, or other drugs. If cefdinir is to be given to penicillin-sensitive patients, caution should be exercised because cross-hypersensitivity among &beta;-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to cefdinir occurs, the drug should be discontinued. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated.</p><p><em>Clostridium difficile</em>&nbsp;associated diarrhea (CDAD) has been reported with use of nearly all&nbsp;antibacterial&nbsp;agents, including Omnicef, and may range in severity from mild diarrhea to fatal&nbsp;colitis. Treatment with antibacterial agents alters the normal&nbsp;flora&nbsp;of the&nbsp;colon&nbsp;leading to overgrowth of&nbsp;<em>C. difficile</em>.</p><p><em>C. difficile</em>&nbsp;produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of&nbsp;<em>C. difficile</em>&nbsp;cause increased morbidity and mortality, as these infections can be&nbsp;refractory&nbsp;to&nbsp;antimicrobial&nbsp;therapy and may require&nbsp;colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful&nbsp;medical history&nbsp;is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against&nbsp;<em>C. difficile</em>&nbsp;may need to be discontinued. Appropriate fluid and&nbsp;electrolyte&nbsp;management, protein supplementation, antibacterial treatment of&nbsp;<em>C. difficile</em>, and surgical evaluation should be instituted as clinically indicated.</p><p><u>Precautions</u></p><p><em>General</em></p><p>Prescribing Omnicef in the absence of a proven or strongly suspected bacterial infection or a&nbsp;prophylactic&nbsp;indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p><p>As with other broad-spectrum antibiotics, prolonged treatment may result in the possible emergence and overgrowth of resistant organisms. Careful observation of the patient is&nbsp;essential. If superinfection occurs during therapy, appropriate alternative therapy should be administered.</p><p>Cefdinir, as with other broad-spectrum antimicrobials (antibiotics), should be prescribed with caution in individuals with a history of colitis.</p><p>In patients with transient or persistent renal insufficiency (creatinine clearance &lt; 30 ml/min), the total daily dose of Omnicef should be reduced because high and prolonged plasma concentrations of cefdinir can result following recommended doses.</p><p><u>Omnicef contains sodium, sodium benzoate and sucrose (sugar)</u></p><p>Omnicef contains sodium. Each 5 ml contains 1.71 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>Omnicef contains sodium benzoate. Each 5 ml contains 5.375 mg sodium benzoate.</p><p>Omnicef contains sucrose (sugar). Each 5 ml contains 2.92 g sucrose (sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Antacids (aluminum- or magnesium-containing)</u></p><p>Concomitant administration of 300-mg cefdinir capsules with 30 ml Maalox&reg; TC suspension reduces the rate (C<sub>max</sub>) and extent (AUC) of absorption by approximately 40%. Time to reach C<sub>max</sub> is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If&nbsp;antacids&nbsp;are required during Omnicef therapy, Omnicef should be taken at least 2 hours before or after the antacid.</p><p><u>Probenecid</u></p><p>As with other &beta;-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination t&frac12;.</p><p><strong>&nbsp;</strong><u>Iron supplements and foods fortified with iron</u></p><p>Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during Omnicef therapy, Omnicef should be taken at least 2 hours before or after the supplement.</p><p>The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.</p><p>Concomitantly administered iron-fortified&nbsp;infant formula&nbsp;(2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. Therefore, Omnicef Powder for Oral Suspension can be administered with iron-fortified infant formula.</p><p>There have been reports of reddish stools in patients receiving cefdinir. In many cases, patients were also receiving iron-containing products. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.</p><p><u>Drug/laboratory test interactions</u></p><p>A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest&reg;, Benedict&#39;s solution, or Fehling&#39;s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix&reg; or Tes-Tape&reg;) be used. Cephalosporins are known to occasionally induce a positive direct Coombs&#39; test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Teratogenic effects</u></p><p>Pregnancy Category B.</p><p>Cefdinir was not&nbsp;teratogenic&nbsp;in rats at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m&sup2;/day) or in rabbits at oral doses up to 10 mg/kg/day (0.7 times the human dose based on mg/kg/day, 0.23 times based on mg/m&sup2;/day). Maternal toxicity (decreased body weight gain) was observed in rabbits at the maximum tolerated dose of 10 mg/kg/day without adverse effects on offspring. Decreased body weight occurred in rat fetuses at &ge; 100 mg/kg/day, and in rat offspring at &ge; 32 mg/kg/day. No effects were observed on maternal reproductive parameters or offspring survival, development, behavior, or reproductive function.</p><p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p><u>Labor and delivery</u></p><p>Cefdinir has not been studied for use during labor and delivery.</p><p><u>Nursing mothers</u></p><p>Following administration of single 600-mg doses, cefdinir was not detected in human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adverse events</u></p><p><em>Clinical trials - Omnicef Powder for Oral Suspension (pediatric patients)</em></p><p>In clinical trials, 2289 pediatric patients (1783 US and 506 non-US) were treated with the recommended dose of cefdinir suspension (14 mg/kg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. Forty of 2289 (2%) patients discontinued medication due to adverse events considered by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. Discontinuations were primarily for gastrointestinal disturbances, usually diarrhea. Five of 2289 (0.2%) patients were discontinued due to rash thought related to cefdinir administration.</p><p>In the US, the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir suspension in multiple-dose clinical trials (N=1783 cefdinir treated patients):</p><p><em>Adverse events associated with cefdinir suspension US trials in pediatric patients (n=1783)<sup>a</sup></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3"><p><strong>Incidence &ge; 1%</strong></p></td><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td rowspan="11"><p><strong>Incidence &lt; 1% but &gt; 0.1%</strong></p></td><td style="vertical-align:top"><p>Cutaneous moniliasis</p></td><td style="vertical-align:top"><p>0.90%</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>0.80%</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia<sup>b</sup></p></td><td style="vertical-align:top"><p>0.30%</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal moniliasis</p></td><td style="vertical-align:top"><p>0.3% of girls</p></td></tr><tr><td style="vertical-align:top"><p>Vaginitis</p></td><td style="vertical-align:top"><p>0.3% of girls</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal stools</p></td><td style="vertical-align:top"><p>0.20%</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>0.20%</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkinesia</p></td><td style="vertical-align:top"><p>0.20%</p></td></tr><tr><td style="vertical-align:top"><p>Increased AST<sup>b</sup></p></td><td style="vertical-align:top"><p>0.20%</p></td></tr><tr><td style="vertical-align:top"><p>Maculopapular rash</p></td><td style="vertical-align:top"><p>0.20%</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>0.20%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;977 males, 806 females&nbsp;<br /><sup>b</sup>&nbsp;Laboratory changes were occasionally reported as adverse events.</p></td></tr></tbody></table><p>Note: In both cefdinir- and control-treated patients, rates of diarrhea and rash were higher in the youngest pediatric patients. The incidence of diarrhea in cefdinir-treated patients &le; 2 years of age was 17% (95/557) compared with 4% (51/1226) in those &gt; 2 years old. The incidence of rash (primarily diaper rash in the younger patients) was 8% (43/557) in patients &le; 2 years of age compared with 1% (8/1226) in those &gt; 2 years old.</p><p>The following laboratory value changes of possible clinical significance, irrespective of relationship to therapy with cefdinir, were seen during clinical trials conducted in the US:</p><p><em>&nbsp;Laboratory value changes of possible clinical significance observed with cefdinir suspension us trials in pediatric patients (n=1783)</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="7"><p><strong>Incidence &ge; 1%</strong></p></td><td style="vertical-align:top"><p>&uarr;Lymphocytes,<br />&darr; Lymphocytes</p></td><td style="vertical-align:top"><p>2%, 0.8%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Alkaline phosphatase</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>&darr;Bicarbonate<sup>a</sup></p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Eosinophils</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Lactate dehydrogenase</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Platelets</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;PMNs,<br />&darr;PMNs</p></td><td style="vertical-align:top"><p>1%, 1%</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&uarr;Urine protein</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td rowspan="11"><p><strong>Incidence &lt; 1% but &gt; 0.1%</strong></p></td><td style="vertical-align:top"><p>&uarr;Phosphorus,<br />&darr;Phosphorus</p></td><td style="vertical-align:top"><p>0.9%, 0.4%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Urine pH</p></td><td style="vertical-align:top"><p>0.80%</p></td></tr><tr><td style="vertical-align:top"><p>&darr;White blood cells,<br />&uarr;White blood cells</p></td><td style="vertical-align:top"><p>0.7%, 0.3%</p></td></tr><tr><td style="vertical-align:top"><p>&darr;Calcium<sup>a</sup></p></td><td style="vertical-align:top"><p>0.50%</p></td></tr><tr><td style="vertical-align:top"><p>&darr;Hemoglobin</p></td><td style="vertical-align:top"><p>0.50%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Urine leukocytes</p></td><td style="vertical-align:top"><p>0.50%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Monocytes</p></td><td style="vertical-align:top"><p>0.40%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;AST</p></td><td style="vertical-align:top"><p>0.30%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Potassium<sup>a</sup></p></td><td style="vertical-align:top"><p>0.30%</p></td></tr><tr><td style="vertical-align:top"><p>&uarr;Urine specific gravity,<br />&darr;Urine specific gravity</p></td><td style="vertical-align:top"><p>0.3%, 0.1%</p></td></tr><tr><td style="vertical-align:top"><p>&darr;Hematocrit<sup>a</sup></p></td><td style="vertical-align:top"><p>0.20%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;N=1387 for these parameters</p></td></tr></tbody></table><p><u>Post-marketing experience</u></p><p>The following adverse experiences and altered laboratory tests, regardless of their relationship to cefdinir, have been reported during extensive postmarketing experience, beginning with approval in Japan in 1991:&nbsp;shock,&nbsp;anaphylaxis&nbsp;with rare cases of fatality, facial and laryngeal edema, feeling of suffocation, serum sickness-like reactions,&nbsp;conjunctivitis, stomatitis,&nbsp;Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis,&nbsp;erythema multiforme,&nbsp;erythema nodosum, acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure,&nbsp;jaundice, increased&nbsp;amylase, acute enterocolitis, bloody diarrhea,&nbsp;hemorrhagic&nbsp;colitis,&nbsp;melena,&nbsp;pseudomembranous colitis,&nbsp;pancytopenia,&nbsp;granulocytopenia,&nbsp;leukopenia,&nbsp;thrombocytopenia, idiopathic thrombocytopenic purpura,&nbsp;hemolytic anemia, acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, idiopathic interstitial pneumonia, fever,&nbsp;acute renal failure,&nbsp;nephropathy, bleeding tendency, coagulation disorder, disseminated intravascular coagulation, upper GI bleed,&nbsp;peptic ulcer,&nbsp;ileus, loss of consciousness,&nbsp;allergic vasculitis, possible cefdinir-diclofenac interaction, cardiac failure, chest pain, myocardial infarction,&nbsp;hypertension, involuntary movements, and&nbsp;rhabdomyolysis.</p><p><u>Cephalosporin class adverse events</u></p><p>The following adverse events and altered laboratory tests have been reported for cephalosporin class antibiotics in general: Allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis,&nbsp;aplastic anemia, hemolytic anemia,&nbsp;hemorrhage, false-positive test for urinary glucose,&nbsp;neutropenia, pancytopenia, and&nbsp;agranulocytosis. Pseudomembranous colitis symptoms may begin during or after&nbsp;antibiotic&nbsp;treatment.</p><p>Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued.&nbsp;Anticonvulsant&nbsp;therapy can be given if clinically indicated.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>https://ade.sfda.gov.sa</u></p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600-mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other &beta;-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.&nbsp;Hemodialysis&nbsp;removes cefdinir from the body. This may be useful in the event of a serious toxic reaction from overdosage, particularly if renal function is compromised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Description</strong></p><p>Omnicef (cefdinir) Powder for Oral Suspension contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6&alpha;, 7&beta; (Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]3-ethenyl-8-oxo-5-thia-1 azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.</p><p>It is slightly soluble in dilute hydrochloric acid and sparingly soluble in 0.1 M pH 7.0 phosphate buffer. The empirical formula is C14H13NsOsS2 and the molecular weight is 395.42. Cefdinir has the structural formula shown below:</p><p><img src="data:image/png;base64,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" alt="" width="485" height="178" vspace="0" hspace="0" border="0" style="width:485px;height:178px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, &beta;-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.</p><p><strong>Mechanism of resistance</strong></p><p>Resistance to cefdinir is primarily through hydrolysis by some &beta;-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability. Cefdinir is inactive against most strains of Enterobacter spp., Pseudomonas spp.,&nbsp;Enterococcus&nbsp;spp., penicillin-resistant streptococci, and&nbsp;methicillin-resistant staphylococci. &beta;-lactamase negative,&nbsp;ampicillin-resistant (BLNAR) H. influenzae strains are typically non-susceptible to cefdinir.</p><p><strong>&nbsp;Antimicrobial activity</strong></p><p>Cefdinir has been shown to be active against most strains of the following microorganisms, both&nbsp;in vitro&nbsp;and in clinical infections as described in&nbsp;Therapeutic indications.</p><p><u>Gram-positive bacteria</u></p><p><em>Staphylococcus aureus</em>&nbsp;(methicillin-susceptible strains only)<br /><em>Streptococcus pneumoniae</em>&nbsp;(penicillin-susceptible strains only)<br /><em>Streptococcus pyogenes</em></p><p><u>Gram-negative bacteria</u></p><p><em>Haemophilus influenzae<br />Haemophilus parainfluenzae<br />Moraxella catarrhalis</em></p><p>The following&nbsp;<em>in vitro</em>&nbsp;data are available, but their clinical significance is unknown.</p><p>Cefdinir exhibits&nbsp;<em>in vitro</em>&nbsp;minimum inhibitory concentrations (MICs) of 1 mcg/ml or less against (&ge; 90%) strains of the following microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p><p><u>Gram-positive bacteria</u></p><p><em>Staphylococcus epidermidis</em>&nbsp;(methicillin-susceptible strains only)<br /><em>Streptococcus agalactiae</em><br />Viridans group streptococci</p><p><u>Gram-negative bacteria</u></p><p><em>Citrobacter koseri<br />Escherichia coli<br />Klebsiella pneumoniae<br />Proteus mirabilis</em></p><p><strong>Susceptibility test methods</strong></p><p>When available, the clinical microbiology laboratory should provide periodic reports that describe the regional/local susceptibility profile of potential&nbsp;nosocomial&nbsp;and community-acquired&nbsp;pathogens. These reports should aid the physician in selecting an&nbsp;antibacterial&nbsp;drug for treatment.</p><p><strong>Dilution techniques</strong></p><p>Quantitative&nbsp;methods are used to determine&nbsp;antimicrobial&nbsp;minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method&nbsp;(broth and/or agar). The MIC values should be interpreted according to criteria provided in Table 1.</p><p><strong>Diffusion techniques</strong></p><p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized method.<sup> </sup>The procedure uses paper disks impregnated with 5 mcg cefdinir to test the susceptibility of bacteria. The disk diffusion interpretive criteria are provided in Table 1.</p><p><em>Table 1: Susceptibility test interpretive criteria for cefdinir</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>Microorganisms<sup>a</sup></strong></p></td><td colspan="3"><p><strong>Minimum Inhibitory Concentration (mcg/ml)</strong></p></td><td colspan="3"><p><strong>Zone Diameter (mm)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>S</strong></p></td><td style="vertical-align:top"><p><strong>I</strong></p></td><td style="vertical-align:top"><p><strong>R</strong></p></td><td style="vertical-align:top"><p><strong>S</strong></p></td><td style="vertical-align:top"><p><strong>I</strong></p></td><td style="vertical-align:top"><p><strong>R</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&ge; 20</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&mdash;</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus parainfluenzae</em></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&ge; 20</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&mdash;</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&ge; 4</p></td><td style="vertical-align:top"><p>&ge; 20</p></td><td style="vertical-align:top"><p>17 - 19</p></td><td style="vertical-align:top"><p>&le; 16</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae<sup>b</sup></em></p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&ge; 2</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&mdash;</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes</em></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&ge; 4</p></td><td style="vertical-align:top"><p>&ge; 20</p></td><td style="vertical-align:top"><p>17 - 19</p></td><td style="vertical-align:top"><p>&le; 16</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup>Streptococci other than&nbsp;<em>S. pneumoniae</em>&nbsp;that are susceptible to penicillin (MIC &le; 0.12 mcg/ml), can be considered susceptible to cefdinir.<br /><sup>b</sup><em>S. pneumoniae</em>&nbsp;that are susceptible to penicillin (MIC &le; 0.06 mcg/ml) can be considered susceptible to cefdinir. Isolates of S. pneumoniae tested against a 1-&mu;g oxacillin disk with oxacillin zone sizes &ge; 20 mm are susceptible to penicillin and can be considered susceptible to cefdinir. Testing of cefdinir against penicillin-intermediate or penicillin-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.</p></td></tr></tbody></table><p>Susceptibility of staphylococci to cefdinir may be deduced from testing penicillin and either cefoxitin or oxacillin. Staphylococci susceptible to oxacillin (cefoxitin) can be considered susceptible to cefdinir.</p><p>A report of &ldquo;Susceptible&rdquo; indicates that antimicrobial is likely to inhibit growth of the&nbsp;pathogen&nbsp;if the antimicrobial compound reaches the concentrations at the site of infection necessary to inhibit growth of the pathogen. A report of &ldquo;Intermediate&rdquo; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of &ldquo;Resistant&rdquo; indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.</p><p><strong>Quality control</strong></p><p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test.<sup> </sup>Standard cefdinir powder should provide the following range of MIC values as noted in Table 2. For the diffusion technique using a 5 mcg disk the criteria in Table 2 should be achieved.</p><p><em>Table 2: Acceptable quality control ranges for cefdinir</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>QC Strain</strong></p></td><td><p><strong>Minimum Inhibitory Concentration (mcg/ml)</strong></p></td><td><p><strong>Zone Diameter (mm)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Escherichia coli</em>&nbsp;ATCC 25922</p></td><td style="vertical-align:top"><p>0.12 - 0.5</p></td><td style="vertical-align:top"><p>24 - 28</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae&nbsp;</em>ATCC 49766</p></td><td style="vertical-align:top"><p>0.12 - 0.5</p></td><td style="vertical-align:top"><p>24 - 31</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus&nbsp;</em>ATCC 25923</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>25 - 32</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus</em>&nbsp;ATCC 29213</p></td><td style="vertical-align:top"><p>0.12 - 0.5</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae&nbsp;</em>ATCC 49619</p></td><td style="vertical-align:top"><p>0.03 - 0.25</p></td><td style="vertical-align:top"><p>26 - 31</p></td></tr></tbody></table><p><strong>Clinical studies</strong></p><p><em>Community-acquired bacterial pneumonia</em></p><p>In a controlled, double-blind study in adults and adolescents conducted in the US, cefdinir&nbsp;BID&nbsp;was compared with cefaclor 500 mg&nbsp;TID. Using strict evaluability and microbiologic/clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:</p><p><em>&nbsp;US community-acquired pneumonia study cefdinir vs cefaclor</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Cefdinir BID</strong></p></td><td style="vertical-align:top"><p><strong>Cefaclor TID</strong></p></td><td style="vertical-align:top"><p><strong>Outcome</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical Cure Rates</p></td><td style="vertical-align:top"><p>150/187 (80%)</p></td><td style="vertical-align:top"><p>147/186 (79%)</p></td><td style="vertical-align:top"><p>Cefdinir equivalent to control</p></td></tr><tr><td style="vertical-align:top"><p>Eradication Rates Overall</p></td><td style="vertical-align:top"><p>177/195 (91%)</p></td><td style="vertical-align:top"><p>184/200 (92%)</p></td><td style="vertical-align:top"><p>Cefdinir equivalent to control</p></td></tr><tr><td style="vertical-align:top"><p><em>S. pneumoniae</em></p></td><td style="vertical-align:top"><p>31/31 (100%)</p></td><td style="vertical-align:top"><p>35/35 (100%)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae</em></p></td><td style="vertical-align:top"><p>55/65 (85%)</p></td><td style="vertical-align:top"><p>60/72 (83%)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>M. catarrhalis</em></p></td><td style="vertical-align:top"><p>10/10 (100%)</p></td><td style="vertical-align:top"><p>11/11 (100%)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>H. parainfluenzae</em></p></td><td style="vertical-align:top"><p>81/89 (91%)</p></td><td style="vertical-align:top"><p>78/82 (95%)</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>In a second controlled, investigator-blind study in adults and adolescents conducted primarily in Europe, cefdinir BID was compared with amoxicillin/clavulanate 500/125 mg TID. Using strict evaluability and clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:</p><p><em>European community-acquired pneumonia study cefdinir vs amoxicillin/clavulanate</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Cefdinir BID</strong></p></td><td style="vertical-align:top"><p><strong>Amoxicillin/Clavulanate TID</strong></p></td><td style="vertical-align:top"><p><strong>Outcome</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical Cure Rates</p></td><td style="vertical-align:top"><p>83/104 (80%)</p></td><td style="vertical-align:top"><p>86/97 (89%)</p></td><td style="vertical-align:top"><p>Cefdinir not equivalent to control</p></td></tr><tr><td style="vertical-align:top"><p>Eradication Rates Overall</p></td><td style="vertical-align:top"><p>85/96 (89%)</p></td><td style="vertical-align:top"><p>84/90 (93%)</p></td><td style="vertical-align:top"><p>Cefdinir equivalent to control</p></td></tr><tr><td style="vertical-align:top"><p><em>S. pneumoniae</em></p></td><td style="vertical-align:top"><p>42/44 (95%)</p></td><td style="vertical-align:top"><p>43/44 (98%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae</em></p></td><td style="vertical-align:top"><p>26/35 (74%)</p></td><td style="vertical-align:top"><p>21/26 (81%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>M. catarrhalis</em></p></td><td style="vertical-align:top"><p>6/6 (100%)</p></td><td style="vertical-align:top"><p>8/8 (100%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>H. parainfluenzae</em></p></td><td style="vertical-align:top"><p>11/11 (100%)</p></td><td style="vertical-align:top"><p>12/12 (100%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><em>Streptococcal pharyngitis/tonsillitis</em></p><p>In four controlled studies conducted in the United States, cefdinir was compared with 10 days of penicillin in adult, adolescent, and pediatric patients. Two studies (one in adults and adolescents, the other in pediatric patients) compared 10 days of cefdinir QD or BID to penicillin 250 mg or 10 mg/kg&nbsp;QID. Using strict evaluability and microbiologic/ clinical response criteria 5 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:</p><p><em>Pharyngitis/tonsillitis studies cefdinir (10 days) vs penicillin (10 days)</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Cefdinir QD</strong></p></td><td style="vertical-align:top"><p><strong>Cefdinir BID</strong></p></td><td style="vertical-align:top"><p><strong>Penicillin QID</strong></p></td><td style="vertical-align:top"><p><strong>Outcome</strong></p></td></tr><tr><td style="vertical-align:top"><p>Adults/Adolescents</p></td><td style="vertical-align:top"><p>Eradication of&nbsp;<em>S.&nbsp; pyogenes</em></p></td><td style="vertical-align:top"><p>192/210 (91%)</p></td><td style="vertical-align:top"><p>199/217 (92%)</p></td><td style="vertical-align:top"><p>181/217 (83%)</p></td><td style="vertical-align:top"><p>Cefdinir superior to control</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Clinical Cure Rates</p></td><td style="vertical-align:top"><p>199/210 (95%)</p></td><td style="vertical-align:top"><p>209/217 (96%)</p></td><td style="vertical-align:top"><p>193/217 (89%)</p></td><td style="vertical-align:top"><p>Cefdinir superior to control</p></td></tr><tr><td style="vertical-align:top"><p>Pediatric Patients</p></td><td style="vertical-align:top"><p>Eradication of&nbsp;<em>S.&nbsp; pyogenes</em></p></td><td style="vertical-align:top"><p>215/228 (94%)</p></td><td style="vertical-align:top"><p>214/227 (94%)</p></td><td style="vertical-align:top"><p>159/227 (70%)</p></td><td style="vertical-align:top"><p>Cefdinir superior to control</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Clinical Cure Rates</p></td><td style="vertical-align:top"><p>222/228 (97%)</p></td><td style="vertical-align:top"><p>218/227 (96%)</p></td><td style="vertical-align:top"><p>196/227 (86%)</p></td><td style="vertical-align:top"><p>Cefdinir superior to control</p></td></tr></tbody></table><p>Two studies (one in adults and adolescents, the other in pediatric patients) compared 5 days of cefdinir BID to 10 days of penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/clinical response criteria 4 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:</p><p><em>Pharyngitis/tonsillitis studies cefdinir (5 days) vs penicillin (10 days)</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Cefdinir&nbsp;BID</strong></p></td><td style="vertical-align:top"><p><strong>Penicillin&nbsp;QID</strong></p></td><td style="vertical-align:top"><p><strong>Outcome</strong></p></td></tr><tr><td style="vertical-align:top"><p>Adults/Adolescents</p></td><td style="vertical-align:top"><p>Eradication of&nbsp;<em>S. pyogenes</em></p></td><td style="vertical-align:top"><p>193/218 (89%)</p></td><td style="vertical-align:top"><p>176/214 (82%)</p></td><td style="vertical-align:top"><p>Cefdinir equivalent to control</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Clinical Cure Rates</p></td><td style="vertical-align:top"><p>194/218 (89%)</p></td><td style="vertical-align:top"><p>181/214 (85%)</p></td><td style="vertical-align:top"><p>Cefdinir equivalent to control</p></td></tr><tr><td style="vertical-align:top"><p>Pediatric Patients</p></td><td style="vertical-align:top"><p>Eradication of&nbsp;<em>S. pyogenes</em></p></td><td style="vertical-align:top"><p>176/196 (90%)</p></td><td style="vertical-align:top"><p>135/193 (70%)</p></td><td style="vertical-align:top"><p>Cefdinir superior to control</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Clinical Cure Rates</p></td><td style="vertical-align:top"><p>179/196 (91%)</p></td><td style="vertical-align:top"><p>173/193(90%)</p></td><td style="vertical-align:top"><p>Cefdinir equivalent to control</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pharmacokinetics and drug metabolism</em></strong></p><p><strong>Absorption</strong></p><p><em>Oral bioavailability</em></p><p>Maximal plasma cefdinir concentrations occur 2 to 4 hours post dose following capsule or suspension administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from 300 mg (7 mg/kg) to 600 mg (14 mg/kg). Following administration of suspension to healthy adults, cefdinir bioavailability is 120% relative to capsules. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%. Cefdinir oral suspension of 250 mg/5 ml strength was shown to be bioequivalent to the 125 mg/5 ml strength in healthy adults under fasting conditions.</p><p><em>&nbsp;Effect of food</em></p><p>The C<sub>max</sub> and AUC of cefdinir from the capsules are reduced by 16% and 10%, respectively, when given with a high-fat meal. In adults given the 250 mg/5 ml oral suspension with a high-fat meal, the C<sub>max</sub> and AUC of cefdinir are reduced by 44% and 33%, respectively. The magnitude of these reductions is not likely to be clinically significant because the safety and efficacy studies of oral suspension in pediatric patients were conducted without regard to food intake. Therefore, cefdinir may be taken without regard to food.</p><p><em>&nbsp;Cefdinir suspension</em></p><p>Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 7- and 14-mg/kg oral doses of cefdinir to pediatric subjects (age 6 months-12 years) are presented in the following table:</p><p>Mean (&plusmn; SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following Administration of Suspension to Pediatric Subjects</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>C<sub>max </sub>(&mu;g/ml)</strong></p></td><td style="vertical-align:top"><p><strong>t<sub>max </sub>(hr)</strong></p></td><td style="vertical-align:top"><p><strong>AUC (&mu;g.hr/ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>7 mg/kg</p></td><td style="vertical-align:top"><p>2.3 (0.65)</p></td><td style="vertical-align:top"><p>2.2 (0.6)</p></td><td style="vertical-align:top"><p>8.31 (2.5)</p></td></tr><tr><td style="vertical-align:top"><p>14 mg/kg</p></td><td style="vertical-align:top"><p>3.86 (0.62)</p></td><td style="vertical-align:top"><p>1.8 (0.4)</p></td><td style="vertical-align:top"><p>13.4 (2.64)</p></td></tr></tbody></table><p><em>&nbsp;Multiple dosing</em></p><p>Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.</p><p><strong>Distribution</strong></p><p>The mean volume of distribution (Vdarea) of cefdinir in adult subjects is 0.35 L/kg (&plusmn; 0.29); in pediatric subjects (age 6 months-12 years), cefdinir Vdarea is 0.67 L/kg (&plusmn; 0.38). Cefdinir is 60% to 70% bound to plasma proteins in both adult and pediatric subjects; binding is independent of concentration.</p><p><em>Skin blister</em></p><p>In adult subjects, median (range) maximal blister fluid cefdinir concentrations of 0.65 (0.33-1.1) and 1.1 (0.49-1.9) &mu;g/ml were observed 4 to 5 hours following administration of 300- and 600mg doses, respectively. Mean (&plusmn; SD) blister C<sub>max</sub> and AUC (0-&infin;) values were 48% (&plusmn; 13) and 91% (&plusmn; 18) of corresponding plasma values.</p><p><em>Tonsil tissue</em></p><p>In adult patients undergoing elective tonsillectomy, respective median tonsil tissue cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were 0.25 (0.220.46) and 0.36 (0.22-0.80) &mu;g/g. Mean tonsil tissue concentrations were 24% (&plusmn; 8) of corresponding plasma concentrations.</p><p><em>Sinus tissue</em></p><p>In adult patients undergoing elective maxillary and&nbsp;ethmoid sinus&nbsp;surgery, respective median sinus tissue cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were &lt; 0.12 ( &lt; 0.12-0.46) and 0.21 ( &lt; 0.12-2.0) &mu;g/g. Mean sinus tissue concentrations were 16% (&plusmn; 20) of corresponding plasma concentrations.</p><p><em>Lung tissue</em></p><p>In adult patients undergoing diagnostic bronchoscopy, respective median bronchial mucosa cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were 0.78 (&lt; 0.06-1.33) and 1.14 (&lt; 0.06-1.92) &mu;g/ml, and were 31% (&plusmn; 18) of corresponding plasma concentrations. Respective median epithelial lining fluid concentrations were 0.29 (&lt; 0.3-4.73) and 0.49 (&lt; 0.3-0.59) &mu;g/ml, and were 35% (&plusmn; 83) of corresponding plasma concentrations.</p><p><em>Middle ear fluid</em></p><p>In 14 pediatric patients with acute bacterial otitis media, respective median middle ear fluid cefdinir concentrations 3 hours after administration of single 7- and 14-mg/kg doses were 0.21 (&lt; 0.09-0.94) and 0.72 (0.14-1.42) &mu;g/ml. Mean middle ear fluid concentrations were 15% (&plusmn; 15) of corresponding plasma concentrations.</p><p><em>CSF</em></p><p>Data on cefdinir penetration into human cerebrospinal fluid are not available.</p><p><strong>Metabolism and excretion</strong></p><p>Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t&frac12;) of 1.7 (&plusmn; 0.6) hours. In healthy subjects with normal renal function, renal clearance is 2.0 (&plusmn; 1.0) ml/min/kg, and apparent oral clearance is 11.6 (&plusmn; 6.0) and 15.5 (&plusmn; 5.4) ml/min/kg following doses of 300- and 600-mg, respectively. Mean percent of dose recovered unchanged in the urine following 300- and 600-mg doses is 18.4% (&plusmn; 6.4) and 11.6% (&plusmn; 4.6), respectively. Cefdinir clearance is reduced in patients with renal dysfunction (see Special populations &ndash; Patients with renal insufficiency).</p><p>Because renal excretion is the predominant pathway of elimination, dosage should be adjusted in patients with markedly compromised renal function or who are undergoing&nbsp;hemodialysis (see&nbsp;Posology and method of administration).</p><p><strong>Special populations</strong></p><p><em>Patients with renal insufficiency</em></p><p>Cefdinir pharmacokinetics were investigated in 21 adult subjects with varying degrees of renal function. Decreases in cefdinir elimination rate, apparent oral clearance (CL/F), and renal clearance were approximately proportional to the reduction in creatinine clearance (CLcr). As a result, plasma cefdinir concentrations were higher and persisted longer in subjects with renal impairment than in those without renal impairment. In subjects with CLcr between 30 and 60 ml/min, C<sub>max</sub> and t&frac12; increased by approximately 2-fold and AUC by approximately 3-fold. In subjects with CLcr &lt; 30 ml/min, C<sub>max</sub> increased by approximately 2-fold, t&frac12; by approximately 5fold, and AUC by approximately 6-fold. Dosage adjustment is recommended in patients with markedly compromised renal function (creatinine clearance &lt; 30 ml/min; see&nbsp;Posology and method of administration).</p><p><em>Hemodialysis</em></p><p>Cefdinir pharmacokinetics were studied in 8 adult subjects undergoing hemodialysis.&nbsp;Dialysis&nbsp;(4 hours duration) removed 63% of cefdinir from the body and reduced apparent elimination t&frac12; from 16 (&plusmn; 3.5) to 3.2 (&plusmn; 1.2) hours. Dosage adjustment is recommended in this patient population, see&nbsp;Posology and method of administration).</p><p><em>Hepatic disease</em></p><p>Because cefdinir is predominantly renally eliminated and not appreciably metabolized, studies in patients with hepatic impairment were not conducted. It is not expected that dosage adjustment will be required in this population.</p><p><em>Geriatric patients</em></p><p>The effect of age on cefdinir pharmacokinetics after a single 300-mg dose was evaluated in 32 subjects 19 to 91 years of age. Systemic exposure to cefdinir was substantially increased in older subjects (N=16), C<sub>max</sub> by 44% and AUC by 86%. This increase was due to a reduction in cefdinir clearance. The apparent volume of distribution was also reduced, thus no appreciable alterations in apparent elimination t&frac12; were observed (elderly: 2.2 &plusmn; 0.6 hours vs young: 1.8 &plusmn; 0.4 hours). Since cefdinir clearance has been shown to be primarily related to changes in renal function rather than age, elderly patients do not require dosage adjustment unless they have markedly compromised renal function (creatinine clearance &lt; 30 ml/min, see&nbsp;Patients with Renal Insufficiency, above).</p><p><em>Gender and race</em></p><p>The results of a meta-analysis of clinical pharmacokinetics (N=217) indicated no significant impact of either gender or race on cefdinir pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Carcinogenesis, mutagenesis, impairment of fertility</em></p><p>The&nbsp;carcinogenic&nbsp;potential of cefdinir has not been evaluated. No mutagenic effects were seen in the bacterial reverse mutation assay (Ames) or&nbsp;point mutation&nbsp;assay at the hypoxanthine-guanine&nbsp;phosphoribosyl transferase&nbsp;locus&nbsp;(HGPRT) in V79 Chinese hamster lung cells. No clastogenic effects were observed&nbsp;<em>in vitro</em>&nbsp;in the structural chromosome aberration assay in V79 Chinese hamster lung cells or&nbsp;<em>in vivo</em>&nbsp;in the micronucleus assay in mouse&nbsp;bone marrow. In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m&sup2;/day).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Citric acid anhydrous</p><p>-&nbsp;&nbsp; Sodium benzoate</p><p>-&nbsp;&nbsp; Trisodium citrate anhydrous</p><p>-&nbsp;&nbsp; Guar gum</p><p>-&nbsp;&nbsp; Xanthan gum</p><p>-&nbsp;&nbsp; Strawberry flavor</p><p>-&nbsp;&nbsp; Magnesium stearate</p><p>-&nbsp;&nbsp; Colloidal silicon dioxide</p><p>-&nbsp;&nbsp; Sugar.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

After reconstitution, the suspension should be used within 10 days. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before opening: Do not store above 30&deg;C.</p><p>&nbsp;</p><p>After reconstitution: Store below 25&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from moisture and heat.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass bottle with a plastic child resistant cap (CRC) and a marked measuring spoon.</p><p><strong>&nbsp;</strong>Pack size: 60 ml (after reconstitution).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To reconstitute invert the bottle and shake to loosen powder. Add 36.5 ml of cooled boiled water in two portions, shake it after each addition until a homogenous suspension is achieved. When first reconstituted allow to stand for five minutes to ensure full dispersion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06 April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>